X0306 4 2019-03-27 0 0001357874 PRECISION BIOSCIENCES INC DTIL 0001397607 Schinazi Raymond F C/O PRECISION BIOSCIENCES, INC. 302 E. PETTIGREW STREET, SUITE A-100 DURHAM NC 27701 1 0 0 0 Stock Option (Right to Buy) 16.00 2019-03-27 4 A 0 34544 0.00 A 2029-03-26 Common Stock 34544 34544 D Convertible Promissory Note 13.60 2019-03-27 4 J 0 502466.00 500000.00 A Common Stock 36946 502466.00 I By RFS Partners, LP The option vests as to 34% of the underlying shares on March 27, 2020 and vests in equal installments at the end of each successive three-month period over the following 24 months. On March 1, 2019, RFS Partners LP ("RFS") acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from Precision BioSciences, Inc. (the "Issuer"). In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the "IPO"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO. The 2019 Note is held of record by RFS. RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the 2019 Note, except to the extent of any pecuniary interest therein. /s/ Abid Ansari, Attorney-in-Fact for Raymond F. Schinazi 2019-03-29